TY - JOUR
T1 - Impact of postoperative venous thromboembolism on Medicare recipients undergoing total hip replacement or total knee replacement surgery
AU - Baser, Onur
AU - Supina, Dylan
AU - Sengupta, Nishan
AU - Wang, Li
AU - Kwong, Louis
PY - 2010/9/1
Y1 - 2010/9/1
N2 - Purpose. The impact of postoperative venous thromboembolism (VTE) during initial hospitalization for total hip replacement (THR) or total knee replacement (TKR) surgery was assessed. Methods. Using Medicare Provider Analysis and Review files, patients who underwent THR, TKR, or hip fracture surgery from 2005 to 2007 were identified using appropriate procedure codes from the International Classification of Diseases, 9th Revision, Clinical Modification. Medicare managed care patients were excluded from the study. Eligible patients were classified as having had deep venous thrombosis (DVT), pulmonary embolism (PE), DVT and PE, or no VTE during their initial hospitalization. Risk adjustment was performed using propensity score matching. Medicare cost, cost to beneficiaries, and cost to primary payers were analyzed to determine riskadjusted differences in outcome measures, including mortality, rehospitalization, bleeding, length of stay, and total health care expenditures related to VTE events. Results. A total of 170,047 patients were identified. Postoperative VTE events occurred in 3,014 patients (1.77%) during their initial hospitalization. Risk-adjusted mortality rates were three to four times higher for patients with VTE compared with those without VTE. Patients with VTE were more likely to be rehospitalized and experience bleeding within 30 days. Risk-adjusted differences in annual mean cost, including Medicare cost and costs to beneficiaries and primary payers, were significantly greater for patients with VTE. Conclusion. Patients who developed VTE after THR or TKR had a higher likelihood of mortality, bleeding, and rehospitalization; were hospitalized longer; and incurred higher costs to Medicare, Medicare beneficiaries, and private payers compared with patients without VTE.
AB - Purpose. The impact of postoperative venous thromboembolism (VTE) during initial hospitalization for total hip replacement (THR) or total knee replacement (TKR) surgery was assessed. Methods. Using Medicare Provider Analysis and Review files, patients who underwent THR, TKR, or hip fracture surgery from 2005 to 2007 were identified using appropriate procedure codes from the International Classification of Diseases, 9th Revision, Clinical Modification. Medicare managed care patients were excluded from the study. Eligible patients were classified as having had deep venous thrombosis (DVT), pulmonary embolism (PE), DVT and PE, or no VTE during their initial hospitalization. Risk adjustment was performed using propensity score matching. Medicare cost, cost to beneficiaries, and cost to primary payers were analyzed to determine riskadjusted differences in outcome measures, including mortality, rehospitalization, bleeding, length of stay, and total health care expenditures related to VTE events. Results. A total of 170,047 patients were identified. Postoperative VTE events occurred in 3,014 patients (1.77%) during their initial hospitalization. Risk-adjusted mortality rates were three to four times higher for patients with VTE compared with those without VTE. Patients with VTE were more likely to be rehospitalized and experience bleeding within 30 days. Risk-adjusted differences in annual mean cost, including Medicare cost and costs to beneficiaries and primary payers, were significantly greater for patients with VTE. Conclusion. Patients who developed VTE after THR or TKR had a higher likelihood of mortality, bleeding, and rehospitalization; were hospitalized longer; and incurred higher costs to Medicare, Medicare beneficiaries, and private payers compared with patients without VTE.
KW - Costs
KW - Economics
KW - Epidemiology
KW - Health benefit programs
KW - Hospitals
KW - Mortality
KW - Postoperative complications
KW - Surgery
KW - Venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=79952032582&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952032582&partnerID=8YFLogxK
U2 - 10.2146/ajhp090572
DO - 10.2146/ajhp090572
M3 - Article
C2 - 20720243
AN - SCOPUS:79952032582
SN - 1079-2082
VL - 67
SP - 1438
EP - 1445
JO - Bulletin. American Society of Hospital Pharmacists
JF - Bulletin. American Society of Hospital Pharmacists
IS - 17
ER -